Natantis selected in the Merck Accelerator Selection 2019!

mkersaudy-kerhoas

Aug 1, 2019

1 min read

Natantis has been selected amongst 30 of a total of 500 entries, to feature in the Merck Accelerator Selection 2019. Antonio Liga and Maiwenn Kersaudy-Kerhoas will attend the Selection Days taking place on the 25th and 26th of November in Darmstadt.

Recent Posts

See All

iSEP-SEQ Medical Research Council study secures 67% recruitment to date

We are delighted to share that the iSEP-SEQ Medical Research Council study has now reached 67% participant recruitment. This milestone marks important progress towards advancing robust pathogen monito

Natantis shortlisted for Royal Society of Medicine's Innovation in Medicine Prize 2025

Natantis Secures £250,000 UK Medical Research Council Funding to Launch NHS Sepsis Trial in Scotland